|Dosage||:||Tablet, Powder and Chewing Tablet|
|Contains||:||Amoxycillin + Potassium Clavulanate|
Rapiclav is a prescription medicine that offers high quality with superior outcomes to treat bacterial infections. It is a combination of two antibiotics Amoxycillin and Potassium Clavulanate which together works for treating treat various types of bacterial infections like respiratory tract infections, genito-urinary tract, skin, bone and infections in the tooth. Amoxycillin is an antibiotic which functions by inhibiting the formation of the protective bacterial covering necessary for bacteria to survive. Clavulanic Acid, on the other hand acts as a beta-lactamase inhibitor reducing resistance to the bacteria as well as enhancing the impact of Amoxycillin working against the bacteria. Besides treating the infection, Rapiclav also kills the microorganisms to prevent further infections.
Rapiclav is manufactured by IPCA Laboratories Ltd., a fully-integrated Indian pharmaceutical company manufacturing over 350 formulations and 80 APIs for various therapeutic segments. The company is one of the world’s largest manufacturers and suppliers of over a dozen APIs. IPCA is a therapy leader in India for anti-malarial medications and also leads in DMARDs (Disease Modifying Anti-Rheumatic Drugs) treatment for rheumatoid arthritis.
Your doctor has prescribed Rapiclav as you may be suffering from bacterial infections.
Bacterial Infections are caused by infectious bacteria which reproduce quickly in the body and may create toxins which can damage tissues and make you very ill.
Bacterial Infections differ from other infections due to the microbes that cause them even though less than one percent of bacteria can make humans sick. Bacterial infections can range from minor illnesses such as strep throat and ear infections to more life-threatening conditions like meningitis and encephalitis. Other Bacterial infections include meningitis, intra-abdominal infections, urinary tract infections, gonorrhea, pelvic inflammatory disease, skin and skin structure infections and acute undifferentiated fever.
Bacterial infections may be marked by localized redness, inflammation, pain or swelling. Common symptoms include inflammation, fatigue, vomiting, coughing and sneezing, fever, diarrhoea and cramping.
Pathogenic bacteria can gain access into the body through a range of access routes. These include cuts, contaminated food or water, close contact with an infected person, physical contact with the faeces of an infected person, getting infected through another person’s coughing or sneezing or by touching contaminated surfaces like taps, toilet handles, nappies or toys.
A bacteria culture test can help find harmful bacteria in your body. A sample is taken from the patient’s blood, urine, skin or other parts of the body during a bacteria culture test. The cells in the sample are put in a special environment in a lab to encourage cell growth. Depending on the type of bacteria, results are often available within a few days. Patients infected by bacteria need to be treated with antibiotics.
As directed by your Physician
As directed by your Physician
The following side-effects may commonly occur when using Rapiclav Tablet. If any of these side-effects worsen or last for a long time, you should consult with your doctor:
The following side-effects may commonly occur in older patients on the use of Rapiclav Tablet. Discuss with your doctor if any of these side-effects last for a long time or are severe:
The following side-effects may commonly occur in children when using Rapiclav Tablet. Discuss with your doctor if any of these side-effects last for a long time or are severe:
Special instructions need to be followed while taking this medicine along with oral contraceptives, which are used to prevent unwanted pregnancy. The use of Rapiclav may affect the natural bacteria of the digestive tract which may lead to decreased hormone re-absorption and reduced the effectiveness of oral contraceptives.
There may be an interaction of Rapiclav with mycophenolate mofetil, which is used to prevent rejection in organ transplantation. The use of Rapiclav with mycophenolate mofetil may decrease the level of mycophenolate mofetil in the blood. Doctors should monitor the patients carefully as soon as possible after antibiotic treatment and during the combination therapy.
Rapiclav Tablet may interact with methotrexate, which is used to treat cancer. Use of penicillins may decrease the excretion of methotrexate which may lead to increased harmful effects.
Safe Disposal of Medication
If there are disposal instructions on the package, please follow the instructions.
If there are medicine take-back programs in your country, you should contact the respective authority to arrange for the disposal of the medicine. For example, in the USA, the Drug Enforcement Administration regularly hosts National Prescription Drug Take-Back events.
If there are no take-back programs, mix the medicine with dirt and place them in a sealed plastic bag. Throw the plastic bag in your household trash. Separately, remove all personal information including the prescription label from the medicine packaging and then dispose off the container.
If specifically indicated on the medicine package that it needs to be flushed down the toilet when no longer needed, perform the required step.
Before you use Rapiclav, tell your doctor if you are allergic to it or its ingredients. Your doctor may prescribe an alternative medicine and update your medical records to record this information.
Before you use Rapiclav Tablet, tell your doctor of your medical history including penicillin allergy, allergy to multiple allergens, allergy to cephalosporins, abnormal functioning of the liver, difficulty in the flow of liver secretions (cholestatic jaundice), abnormal functioning of the kidney, inflammation of the colon due to bacteria (Clostridium difficile Associated Diarrhea), mononucleosis (an infectious condition caused by a virus), drug resistance, patients undergone urine testing to detect sugar levels, patients with history of asthma, hay fever and hives, or use of oral contraceptives. A life-threatening allergic reaction is observed in the patient with a history of allergy with penicillin and multiple allergens.
An inflammation of the liver (hepatitis) and decrease flow of digestive fluid from liver (cholestatic jaundice) is observed in patients with a history of abnormal liver functioning. Use of this medicine may cause convulsions in patients with abnormal functioning of the kidney or taking a drug in high dose.
Use of Rapiclav in patients with Clostridium difficile associated diarrhea (CDAD) may kill the natural bacteria of intestine which lead to severe diarrhea. Redness and rashes of the skin may be observed in patients with a history of mononucleosis. Using this medicine in improperly diagnosed bacterial infection may lead to the development of resistance in bacteria against the drug.
The use of Rapiclav Tablet may change blood clotting parameter (prothrombin time). Use of Rapiclav may increase the prothrombin time. Patients should be monitored carefully.
The use of this medicine may change blood estrogen level. Rapiclav may decrease the levels of blood estrogen hormone (estriol, estriol-glucuronide, conjugated estrone, and estradiol) during pregnancy.
The use of Rapiclav Tablet may change liver enzymes (aspartate aminotransferase and alanine aminotransferase). Abnormal functioning of the liver and elevated levels of liver enzymes are observed in patients taking Rapiclav for a long time.
Rapiclav Tablet should be used only when required in patients who are pregnant or planning to become pregnant. Rapiclav should be avoided during pregnancy unless it is necessary during pregnancy. Rapiclav Tablet should be used while breastfeeding only when required. Rapiclav may pass into breast milk and can cause diarrhea and fungal infection in the breastfed infant, so Rapiclav should only be used with precaution or after assessment of risks and benefits of the drug during breastfeeding by the doctor. Consult with your doctor on the use of Rapiclav Tablet, if you are trying to conceive.
Limit drinking alcohol with Rapiclav.
Older patients may have a higher incidence of side-effects when using Rapiclav Tablet. Elderly patients may see an increased risk of inflammation of the liver (hepatitis), difficulty in the flow of bile from liver (cholestatic jaundice), and increased liver enzymes.
Younger patients may have a higher incidence of side-effects with Rapiclav Tablet. Younger patients may see an increased risk of diarrhea, skin rashes, hives, diaper area rashes, and tooth discoloration.
If this medicine is used for long-term may cause complications like inflammation of the liver (hepatitis), the decrease in bile flow from liver (cholestatic jaundice) and increased levels of liver enzymes.
Excessive growth of non-sensitive bacteria (overgrowth of non-susceptible organisms)
Patients taking Rapiclav are at an increased risk. Prolong use of Rapiclav treatment may develop excessive growth of non-sensitive bacteria against medicines.
Patients taking allopurinol
Such patients are at an increased risk when using Rapiclav. These patients may develop an allergic skin reaction.Patients with amoxicillin sensitive bacterial (amoxicillin-susceptible organism) infection
Patients with amoxicillin-susceptible organism are at increased risk when using Rapiclav. Rapiclav may cause an infection in such patients. Changing Rapiclav therapy to only amoxicillin therapy should be recommended after proper clinical guidance.
Abnormal functioning of the kidney
Patients with abnormal functioning of the kidney or taking higher doses of Rapiclav are at an increased risk when using Rapiclav. Use of Rapiclav in these patients may cause convulsions. Dose adjustment is recommended in such patients.
Development of drug-resistant bacteria
Using Rapiclav in the improper diagnosis of bacterial infection may cause the development of resistance in bacteria for the drug.
The patients who are using Rapiclav are at an increased risk of occurrence of superinfections caused by bacterial or fungal pathogens. If superinfection occurs, discontinue the use of Rapiclav.
Patients with mononucleosis (an infectious condition caused by virus)
Such patients are at an increased risk when using Rapiclav. Rapiclav cause redness of the skin (erythematous skin rash) in patients with mononucleosis. Such patients should not use this medicine.
Clostridium difficile associated diarrhea
The patients using antibacterial drugs are at increased risk while using this medicine. The use of Rapiclav may cause mild diarrhea to possibly fatal colitis. Antibacterial agents alter the organisms present in the colon causing overgrowth of the Clostridium difficile bacteria. If Clostridium difficile associated diarrhea (CDAD) occurs discontinue the use of Rapiclav. The suitable treatment for treatment of this kind of diarrhea includes an appropriate fluid and electrolyte management, protein supplementation, antibacterial drug treatment, and surgical evaluation as clinically indicated.
Abnormal functioning of the liver
Such patients are at an increased risk when using this medicine. These patients may experience conditions such as abnormal functioning of the liver, inflammation of the liver (hepatitis), decrease in bile flow from liver (cholestatic jaundice) and fatal conditions due to liver failure. Precaution in dose adjustment and regular monitoring of liver function is recommended in patients with abnormal functioning of the liver.
Patients with blisters and red, scaly rash with bumps under the skin (acute generalized exanthemous pustulosis)
The patients with these skin conditions are at increased risk when using this medicine. Using Rapiclav may cause fever and blisters with red, scaly rash and bumps under the skin (feverish generalized erythema) along with pus-containing blisters (pustula) in patients with acute generalized exanthemous pustulosis. Patients should stop or avoid taking Rapiclav on the occurrence of feverish generalized erythema with pustules.
Use of anticoagulants with Rapiclav
Patients taking anticoagulants with Rapiclav are at increased risk when using this medicine. These patients may experience increased bleeding time (prothrombin time). Careful monitoring and dose adjustment of anticoagulants are recommended in patients using Rapiclav.
Patients with reduced urination
Patients with reduced urination are at increased risk when using Rapiclav. Using Rapiclav in patients with reduced urine output may cause cloudiness due to crystals in the urine (crystalluria) when taken parenterally. Appropriate fluid intake and excretion of urine are recommended in patients. A regular checkup is necessary for patients with bladder catheters.
When two or more medicines are taken together, it can change how the medicines work and increase the risk of side-effects. In medical terms, this is called as a Drug Interaction.
Your doctor’s guidelines may need to be followed while taking this medicine along with false-positive reactions. Patients using Rapiclav or amoxicillin alone during testing of glucose in urine using Benedict’s solution, Fehling’s solution or testing kit may see an increased risk of false positive reactions. Enzymatic glucose oxidase reactions based glucose test should be recommended in such patients.
Rapiclav Tablet interacts with allopurinol, which is used to treat redness and tenderness in the joints (gout). Patients using amoxicillin with allopurinol may experience the increased occurrence of rashes as compared to patients taking amoxicillin alone. It is unknown whether the increased incidence of rashes is due to the combined usage of amoxicillin with allopurinol or due to increased levels of uric acid (hyperuricemia) in patients.
There may be an interaction of Rapiclav with oral anticoagulants (acenocoumarol and warfarin), which are used to prevent blood clotting. The use of amoxicillin in combination with oral anticoagulants may abnormally increase the bleeding time in patients. Careful monitoring of blood clotting parameter, with the use or withdrawal of amoxicillin and dose adjustment of oral anticoagulants, is recommended in patients using anticoagulants with Rapiclav.
Rapiclav Tablet may interact with probenecid, which is used to treat redness and tenderness in the joints (gout). Probenecid decreases the secretion of amoxicillin in the kidney. The use of Rapiclav with probenecid may increase the level of amoxicillin in the blood. Patients should not use probenecid with Rapiclav.
If you use too much of this medicine, it could lead to dangerous levels of the medicine in your body. In such cases, symptoms of an overdose may include: